thisdrug what a medicine's name tells you

WHO naming stem · suffix · 20 listed names

-gliptin

This page was written with AI.

dipeptidyl aminopeptidase–IV inhibitors

WHO's definition, quoted as written in the 2024 stem book

5 of 20 names appear in these lists: 4 in the US list (FDA Drugs@FDA) and 5 in the EU central list (EMA); 5 have national brands in at least one EU/EEA country.

Names only. This page is about -gliptin as a part of a name. It has nothing on uses, doses, side effects or interactions of any medicine that carries it, and nothing here is medical advice. Ask a pharmacist or doctor about the medicine itself.

Where it sits in a name

WHO writes the stem as -gliptin. So the letters gliptin sit at the end of the name (…gliptin).

All 20 names WHO lists under -gliptin

These are the INN in group (a) of Part IV of the stem book: names in which WHO says the stem is used as defined. The stem is marked where WHO places it. A-Z as WHO lists them.

Beside each name: the brand names it appears under in the US list (FDA Drugs@FDA) and the EU central list (EMA), or that neither list carries it. 5 of 20 names appear in these lists: 4 in the US list (FDA Drugs@FDA) and 5 in the EU central list (EMA); 5 have national brands in at least one EU/EEA country. Each brand opens in this site's brand lookup. A name is found when the agency's ingredient name is the same name once salt words such as hydrochloride or sodium are set aside (the list of those words); where WHO's own name carries such a word (estradiol valerate), the agency must write the same words. A spelling that differs only by the INN letter rules (ph for f, y for i) is found too and shown. Under each name that one or more EU/EEA countries authorise under a national brand of their own (through that country's agency, so not in the EU central list), a line now gives the number of those countries and their codes, from EMA's Article 57 data, and opens the country lookup at that name. A name with none of these lines may still be sold elsewhere, or in Europe only under its own generic name.

  1. alogliptin
    US brands: NESINA
    in combination: KAZANO with metformin; OSENI with pioglitazone
    EU (central) brands: Vipidia
    in combination: Incresync with pioglitazone; Vipdomet with metformin
  2. anagliptin
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  3. bisegliptin
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  4. carmegliptin
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  5. cofrogliptin
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  6. denagliptin
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  7. dutogliptin
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  8. evogliptin
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  9. garvagliptin
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  10. gemigliptin
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  11. gosogliptin
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  12. linagliptin
    US brands: TRADJENTA
    in combination: GLYXAMBI with empagliflozin; JENTADUETO with metformin; JENTADUETO XR with metformin; TRIJARDY XR with empagliflozin + metformin
    EU (central) brands: Trajenta
    in combination: Glyxambi with empagliflozin; Jentadueto with metformin
  13. melogliptin
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  14. omarigliptin
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  15. prusogliptin
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  16. saxagliptin
    US brands: ONGLYZA (discontinued in FDA listings)
    in combination: KOMBIGLYZE XR (discontinued in FDA listings) with metformin; QTERN (discontinued in FDA listings) with dapagliflozin; QTERNMET XR (discontinued in FDA listings) with dapagliflozin + metformin
    EU (central) brands: Onglyza
    in combination: Komboglyze with metformin; Qtern with dapagliflozin; Qtrilmet (withdrawn) with dapagliflozin + metformin
  17. sitagliptin
    US brands: BRYNOVIN, JANUVIA, ZITUVIO
    in combination: JANUMET with metformin; JANUMET XR with metformin; STEGLUJAN with ertugliflozin; ZITUVIMET with metformin; ZITUVIMET XR with metformin; JUVISYNC (discontinued in FDA listings) with simvastatin
    in combination: Efficib with metformin; Janumet with metformin; Ristfor with metformin; Sitagliptin / Metformin hydrochloride Mylan with metformin; Sitagliptin / Metformin hydrochloride Sun with metformin; Steglujan with ertugliflozin; Velmetia with metformin; Sitagliptin / Metformin hydrochloride Accord (lapsed) with metformin
  18. teneligliptin
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  19. trelagliptin
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  20. vildagliptin
    US brands: none found
    EU (central) brands: Galvus, Jalra, Xiliarx
    in combination: Eucreas with metformin; Icandra with metformin; Vildagliptin / Metformin hydrochloride Accord with metformin; Zomarist with metformin

US list: Drugs@FDA, from the FDA Drugs@FDA data (openFDA bulk file), checked . It keeps discontinued brands, marked here as FDA marks them.

EU (central) list: EMA medicines list, European Medicines Agency (EMA), checked . Medicines authorised for the whole EU through EMA only: a brand authorised by one country's own agency is not in it. Source: European Medicines Agency (EMA), medicines list, checked 2026-09-24.

EU/EEA national lists: European Medicines Agency (EMA), Article 57 product data, downloaded (EMA's Article 57 page). Brand names authorised by each country's own agency, as the country lookup reads them; a product named after its substance and maker ("Paracetamol Teva") is not counted as a brand, and EU central authorisations are not counted as a country. GB in a list is Northern Ireland, which EMA's data carries alongside the EU/EEA countries.

Decode another name

Decoded

alogliptin

Listed INNCarries 2 WHO stems, most specific first: -gliptin …

  • -gliptinend of the nameWHO lists it hereWHO definition: dipeptidyl aminopeptidase–IV inhibitors
  • gliinside the nameWHO lists it hereWHO definition: antihyperglycaemics

“alogliptin” is an INN that WHO lists under -gliptin, gli in the 2024 stem book.

The same decoder as the front page: it reads the letters of a name against all 482 WHO stems, in your browser.

Source and licence

The definition of -gliptin (Part II B) and the 20 names (Part IV, group (a)) are from Use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances, 2024 (World Health Organization, Stem book 2024 (ISBN 978-92-4-009938-8); covers proposed INN Lists 1-129). Checked .

Adapted from: Use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances, 2024. Geneva: World Health Organization; 2024. Licence: CC BY-NC-SA 3.0 IGO. This adaptation was not created by WHO; WHO is not responsible for its content or accuracy and does not endorse this site. The data file stems.json is shared under the same licence.

Made with AI tools. · Privacy